This seems like an area in which companion diagnostics would really help, but not sure how much tougher they'd be to develop for I-O drugs (it's tough enough for targeted therapies). I haven't looked, is anyone trying?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.